DGX vs GILD · P/E 22, rev $5.94B vs P/E 18, rev $7.80B
Quest Diagnostics Incorporated (DGX) versus Gilead Sciences Inc (GILD) — a side-by-side from cached financials, not a winner call.
Quest Diagnostics Incorporated (DGX) is a diagnostics & research company listed on US.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
Latest reported DGX revenue for 2026-06-30 was $5.94B. Net income was $572.0M. DGX currently screens at market cap $19.94B and trailing P/E 22.4.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
DGX currently screens at market cap $19.94B and trailing P/E 22.4. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Not investment advice. Open the DGX and GILD stock pages for the full models.
Not investment advice.